WIA Biopharma Standard Guide

Contents

Chapter 1The World of Biopharmaceuticals: From Molecule to PatientWhat a biologic is, how the major product classes differ, which cells make them, and where the WIA-BIO-016 standard sits in the path from a protein sequence to…

1.1 What Makes a Biologic Different
1.2 The Product Classes
1.3 Expression Systems
1.4 Post-Translational Modifications
1.5 The Therapeutic Landscape
1.6 The Development Lifecycle
1.7 Where WIA-BIO-016 Fits and How This Book Is Organised

Chapter 2Molecular Characterization and Quality AttributesHow a biologic is measured, which of those measurements become critical quality attributes, and how WIA-BIO-016 records them.

2.1 Critical Quality Attributes and Quality by Design
2.2 Mass Spectrometry: Intact Mass and Peptide Mapping
2.3 Glycan Analysis
2.4 Higher-Order Structure
2.5 Size Variants and Aggregation
2.6 Charge Variants and Process-Related Impurities
2.7 Putting It Together: Attributes, Methods and Example Limits
2.8 Pitfalls: Why One Number Is Never "Purity"

Chapter 3The WIA-BIO-016 Data ModelHow the standard records a biologic, its characterization, its assays, its process and its regulatory status: the TypeScript type model in types.ts, read field…

3.1 Design of the Model: the Types Are the Data Format
3.2 Product Identity Types
3.3 Characterization Records
3.4 Assay Records
3.5 Process and Regulatory Records
3.6 Constants, Errors and Result Types
3.7 Serialising to JSON
3.8 Chapter Summary

Chapter 4Binding, PK/PD and the Calculation APIHow strongly a biologic binds its target, how long it stays in the body, and how much effect a given concentration produces: the equations behind these three…

4.1 Equilibrium Binding and calculateBindingAffinity()
4.2 Binding Kinetics and calculateKinetics()
4.3 Pharmacokinetic Core and calculatePharmacokinetics()
4.4 From Parameters to a Dose Regimen
4.5 Pharmacodynamics and calculatePharmacodynamics()
4.6 Known Defects: What to Teach, Test and Work Around
4.7 Worked Examples: Appendix A Recomputed
Review Questions

Chapter 5Immunogenicity, Stability and FormulationHow the immune system answers a therapeutic protein, how a protein ages in the vial, and how formulation ties the two together, read through WIA-BIO-016 §6–7…

5.1 Anti-Drug Antibodies: What the Immune System Sees
5.2 The Tiered ADA Assay
5.3 The WIA Immunogenicity Risk Score
5.4 Reducing Immunogenicity
5.5 Forced Degradation: Learning How the Molecule Fails
5.6 The Stability Programme and ICH Q5C
5.7 Arrhenius Kinetics and Shelf-Life Prediction
5.8 Formulation: Choosing the Environment the Protein Lives In

Chapter 6The Development Protocol: From Candidate Validation to BiosimilarityHow the measurements of Chapters 2–5 are chained into an ordered, gated workflow; what validateDrugCandidate() and assessBiosimilarity() actually decide; and…

6.1 The BIO-016 Evidence Workflow as a Protocol
6.2 Candidate Gating with validateDrugCandidate()
6.3 Manufacturing Process Data
6.4 Comparability after a Process Change versus Biosimilarity
6.5 Analytical Similarity
6.6 The Clinical Bridge
6.7 The Protocol at a Glance

Chapter 7Regulatory Submission, Conformance and CertificationHow the records and calculations of WIA-BIO-016 find their place in a Common Technical Document, what data integrity obligations fall on the tools built around…

7.1 The CTD Structure and the Main Application Routes
7.2 CMC Essentials for a Biologic
7.3 The Guidelines Behind the Specification
7.4 Data Integrity for Tools Built on the SDK
7.5 Testing an Implementation
7.6 WIA Conformance Evidence
7.7 What a Certificate Can and Cannot Claim

Chapter 8Next-Generation Biologics and the Evolution of the StandardWhere the WIA-BIO-016 data model stops, what the newer modalities need from it, and how to evolve the specification, SDK and CLI without breaking the records…

8.1 Modalities the v1.0 Model Under-covers
8.2 Antibody-Drug Conjugates: from Mean DAR to Distribution
8.3 Continuous Manufacturing, PAT and Real-Time Release
8.4 AI and Machine Learning in Discovery and Developability
8.5 Regulatory Directions
8.6 Roadmap for WIA-BIO-016 v1.x and v2
Review Questions

About this book

What a biologic is, how the major product classes differ, which cells make them, and where the WIA-BIO-016 standard sits in the path from a protein sequence to a medicine in a patient's hands.

A conventional small-molecule drug such as aspirin or metformin is a single, fully defined chemical structure. Its identity can be written down as one formula, its purity measured against that formula, and two batches made by different factories are, for practical purposes, the same substance. A biopharmaceutical, or biologic, is different in almost every one of these respects. It is a large molecule, usually a protein or a nucleic acid, produced by living cells rather than assembled by stepwise chemical synthesis, and what comes out of a production run is never a single molecular species but a population of closely related variants.